



INFINite - The International Network for Inflammation

Standalone event

Oct 30-Nov 2

ON THE
SURFACE
AND BEYOND

SC-TWN-apremilast-00046-0923

Introducing your steering committee peers

Melinda Gooderham
Assistant Professor; Consultant Physician
Queen's University; Peterborough
Regional Health Centre
Ontario, Canada



Laura Coates
NIHR Clinician Scientist;
Associate Professor at University of Oxford
Nuffield Department of Orthopaedics,
Rheumatology and Musculoskeletal Sciences;
University of Oxford
Oxford, United Kingdom



Marjolein de Bruin-Weller
Dermatologist and Head of the National
Expertise Center of Atopic Dermatitis
University Medical Center of Utrecht
Utrecht, The Netherlands




Philip Mease
Director of Rheumatology Research;
Clinical Professor; Rheumatologist
Swedish Health Services, Providence St Joseph Health;
University of Washington; Seattle Rheumatology Associates
Washington, United States



Peter Foley
Associate Professor; Director of Research;
Head of Dermatology Research
University of Melbourne; Skin Health
Institute; St Vincent's Hospital Melbourne
Melbourne, Australia



We invite your insights on the most appropriate mix-and-match agenda



**Live session:
All delegates**

Harnessing our capabilities: Shared decision-making in the clinic

Recentering: Focus on practical approaches to assessing disease severity and impact

Forward together: Collaboration in multidisciplinary care

Overcoming challenges to achieve long-term treatment success

ON THE
SURFACE
AND BEYOND



Note: This is an overview of the agenda. Please refer to each topic for more details

AD, atopic dermatitis; PCP, primary care physician; PRO, patient-reported outcome; PsA, psoriatic arthritis; PsO, psoriasis; RWE, real-world evidence.

AD: Agenda

Time	Topic and outline	Duration (mins)	Proposed speakers
Oct 30 3:30 PM - 3:50PM	Looking beneath the surface: Understanding the patient experience in AD		
	Factors impacting QoL and treatment satisfaction for patients with AD	20	Melinda Gooderham
Oct 31 3:00 PM - 3:30PM	Exposing the foundations : Understanding disease and treatment mechanisms in AD		
	Understanding the latest in disease mechanism for AD	10	Jonathan Silverberg
	Examining MoA for new treatments in AD	20	Melinda Gooderham and Marjolein de Bruin-Weller
Oct 31 3:30 PM - 4:10PM	New horizons: Latest data and future clinical perspectives in AD		
	Getting to grips with the latest clinical trials data	20	Richard Warren
	Looking towards ongoing/future trials	20	Richard Warren and Alan Irvine

ON THE
SURFACE
AND BEYOND



AD, atopic dermatitis; MoA, mechanism of action; QoL, quality of life.
For corresponding references, please see slide notes.

PsO: Agenda

	Topic and outline	Duration (mins)	Proposed speakers
Oct 30 4:00 PM - 4:50PM	Pushing the boundaries with precision: Addressing key challenges in PsO management		
	Challenges in the diagnostic pathway; the importance of early diagnosis	30	Diamant Thaci and Laura Coates
	Personalizing the PsO treatment approach	20	Ulrich Mrowietz
Oct 31 4:30 PM - 5:00PM	New horizons: Latest data and future clinical perspectives in PsO		
	Relating the latest trials and RWE to the clinic	30	Andreas Pinter and Peter Foley

ON THE
SURFACE
AND BEYOND



IPC, International Psoriasis Council; PsA, psoriatic arthritis; PsO, psoriasis; RCT, randomized controlled trial; RWE, real-world evidence. For corresponding references, please see slide notes.

PsA: Agenda

	Topic and outline	Duration (mins)	Proposed speakers
Oct 30 4:30 PM - 5:05 PM	Pushing the boundaries with precision: Addressing key challenges in management of PsA		
	Personalizing the PsA treatment approach	15	Philip Mease
	Embracing MRI; a hot topic in PsA management	20	Xenofon Baraliakos
Nov 1 3:30 PM - 4:00 PM	New horizons: Latest data and future clinical perspectives in PsA		
	Relating the latest trials and RWE to the clinic	30	Carlo Selmi; Alexis Ogdie; Frank Behrens



PsO and PsA combined: Agenda

	Topic and outline	Duration (mins)	Proposed speakers
Nov 1 3:00 PM - 3:45PM	Avoiding the cracks: Delivering patient-centered care for patients with PsO and PsA (45 mins)		
	Understanding disease heterogeneity and impact to patient QoL	30	Álvaro González-Cantero and Alexis Ogdie
	Staying connected with your patient	15	Ulrich Mrowietz
Nov 1 4:00 PM - 4:15PM	Navigating the pathway: Insights from disease and treatment mechanisms in PsO and PsA (15 mins)		
	Examining MoA for new treatments in PsO and PsA	15	Philip Mease Peter Foley and Stefan Siebert

ON THE
SURFACE
AND BEYOND



- Each session requiring speakers in Topics 8 and 9 will be presented by at least two speakers: a dermatologist and a rheumatologist

MoA, mechanism of action; PDE4, phosphodiesterase 4; PsA, psoriatic arthritis; PsO, psoriasis; QoL, quality of life. For corresponding references, please see slide notes.

All delegates: Agenda

	Topic and outline	Duration (mins)	Proposed speakers
Oct 30 5:00 PM – 5:30PM	Recalibrating understanding: The immune system and its role in inflammatory diseases		
	Revisiting the immune system and the mechanisms underlying inflammatory diseases	30	Alberto Mantovani
Oct 31 4:00 PM – 4:30PM	Infinite value: The importance of RWE and PROs		
	Bringing insights from the latest trials and RWE to the clinic	30	Melinda Gooderham Philip Mease

ON THE
SURFACE
AND BEYOND



AD, atopic dermatitis; PRO, patient-reported outcome; PsA, psoriatic arthritis; PsO, psoriasis; RCT, randomized controlled trial; RWE, real-world evidence.
For corresponding references, please see slide notes.

Live sessions (speakers and times TBC)

Live sessions to be conducted on Nov 2nd

	Topic and outline	Duration (mins)	Proposed speakers
Nov 2 3:00-3:30 PM (1) 10:00-10:30 PM (2)	Harnessing our capabilities: Multidisciplinary collaboration in clinical decision-making	30	(1) Peter Foley and Colin Theng (2) Phil Mease and Melinda Gooderham
Nov 2 3:30-4:00 PM (1) 10:30-11:00 PM (2)	Recentering: Practical approaches to understanding and overcoming barriers to long-term treatment success	30	(1) Richard Warren and Yik Weng Yew (2) Melinda Gooderham and Marjolein de Bruin-Weller



每日總時數

- **Oct 30: 135 mins**

- AD: 20 mins
- PsO: 50 mins
- PsA: 35 mins
- All delegates: 30 mins

- **Oct 31: 130 mins**

- AD: 70 mins
- PsO: 30 mins
- All delegates: 30 mins

- **Nov 1: 90 mins**

- PsA: 30 mins
- PsO+PsA: 60 mins

- **Nov 2: 120 mins**

- Live sessions: 120 mins

